There is no standard treatment to maintain or improve the response a patient has to receiving a stem cell transplant from a donor. In this study, researchers are evaluating the safety and effectiveness of an oral (given by mouth) drug called azacitidine (also known as CC-486) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) who are receiving such “allogeneic” stem cell transplants.
An injected form of azacitidine is already approved for treating MDS and certain leukemias. The oral form of azacitidine is considered investigational. In this study, it is hoped that giving this drug to patients with AML or MDS following their transplants will lower the chance that their disease will return.